The first disulfide linkage-employing drug conjugate that exploits the reversible nature of this
unique covalent bond was recently approved for human use. Increasing numbers of drug …

The major dose-limiting toxicity of interleukin-2 (IL-2) and of immunotoxin (IT) therapies is
vascular leak syndrome (VLS). VLS is characterized by an increase in vascular permeability …

Abstract Each year, the American Cancer Society estimates the number of new cancer cases
and deaths expected in the United States in the current year and compiles the most recent …

Abstract IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–
specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates …

Background In the current epidemic of Ebola virus disease in western Africa, many aid
workers have become infected. Some of these aid workers have been transferred to …

Single-walled carbon nanotubes (CNTs) emit heat when they absorb energy from near-
infrared (NIR) light. Tissue is relatively transparent to NIR, which suggests that targeting …

Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment
linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell …

The clinical activity of rituximab, a chimeric monoclonal antibody which binds to the CD20
antigen, was evaluated as a single first-line therapy for patients with follicular non-Hodgkin …

Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …

Background Hairy-cell leukemia that is resistant to treatment with purine analogues,
including cladribine, has a poor prognosis. We tested the safety and efficacy of an …